Closed Processing for Cell Therapies: Engineering Risk Reduction and Patient Safety during Manufacturing

Closed Processing for Cell Therapies: Engineering Risk Reduction and Patient Safety during Manufacturing

May 1, 2014

Production of patient-specific cell-based therapies (PSCT) presents unique scale and cost challenges not seen in pharmaceuticals and biologics manufacturing.

Click here to access the GenEng website.